![Aaron Edwards Profile](https://pbs.twimg.com/profile_images/1568093047853809666/mX0k40O4_x96.jpg)
Aaron Edwards
@aedwards02
Followers
1K
Following
3K
Statuses
2K
Co-Founder/CEO @KiraGenBio | MS/MBA @HarvardHBS | Past CAR-T editing @beamtx & @bluebirdbio.
Boston, MA
Joined March 2009
For the first time, allo CAR-T therapy has OUTPERFORMED auto CAR-T in the same patients! This offers hope for faster, scalable solutions—and we’re excited about how it validates our approach @KiraGenBio to tackling TME suppression. Let’s dive into it. 🧵
5
36
168
@GeneInvesting @Nicole_Paulk @elonmusk I’m waiting on bated breath to see how they anticipate speeding up the FDA after they’ve slashed their budget.
1
0
1
@GeneInvesting @Nicole_Paulk @elonmusk I wouldn’t be relying on Elons wording to be what the actual reality is. These cuts are for all grants coming from the NIH, not just to those “institutions” he is trying to shit on. @Nicole_Paulk is spot on. This will impact industry, primarily early stage companies like ours
1
0
1
@NEObioMATRIX @EricTopol @NatureMedicine Is that your response to all things you don’t want to believe to be true?
0
0
0
Structural, systemic change is needed. A broad overhaul can enable better and more efficient oversight w/out compromising effectiveness. These improvements typically require more funding, not less. The scandals mentioned were also heavily obfuscated by corporate misconduct—reducing FDA resources would only exacerbate that problem, not solve it.
1
0
1
@GeneInvesting @DOGE @elonmusk Or why not take 1% of the defense budget and double these orgs budgets to ensure they can hire top talent and do what you say while simultaneously ensuring American innovation remains in pipeline? Sure, bring on some reform, but don’t start with budget cuts.
1
0
1
@yaireinhorn @unusual_whales @BillAckman But these changes are legit already negatively impacting people and research groups. By the time your “wait and see” approach pans out it will be too late to fix. When people at ALL levels in science are broadly against this, I suggest you reconsider your take on these cuts.
0
0
0
@GeneInvesting @elonmusk When even conservative leaning biopharma leaders are in absolute SHOCK by this and claim it will destroy innovation and progress… I’d listen up. Relying on business and tech leaders to know the intricacies of a system and how cuts will impact us is naive at best
1
0
1
RT @JMaraganore: And one more point pertinent for today… 7. We MUST foster the best science in the world with a thriving academic research…
0
1
0
@yaireinhorn @unusual_whales @BillAckman I’m simply referring to your argument in support of these broad based cost cuts. Those will not help any of the issues you point out. Let’s keep focused on that. A mindset change or structural/organizational change does NOT have to be equivalent to cost cuts.
1
0
0
@yaireinhorn @unusual_whales How would cost cuts have solved the example you pose above? Perhaps the changes needed aren’t broad based cuts? Lots of examples to actually argue with structural change needs to come MORE funding. These orgs lack the people required to oversee the medical innovation of today.
1
0
0
The ‘shakedown’ narrative also ignores reality. The FDA isn’t perfect, but it plays a critical role in ensuring safety and efficacy—something China’s regulatory environment doesn’t prioritize in the same way. Faster trials don’t mean better outcomes; they often mean weaker oversight. The US has a higher bar for patient protection, and that’s a good thing. If anything, biotech innovation thrives because of rigorous standards, not in spite of them.
2
0
2
@yaireinhorn @unusual_whales Finding flaws in a system does NOT justify burning the entire system down.
0
0
1
They have been inspected. By every administration. Does change need to happen? 100%. But sweeping, reactionary overhauls risk destabilizing an entire ecosystem. Early-stage biotech—especially those of us relying on NIH & SBIR funding—depends on a functioning system. Thoughtful reform? Yes. Burn-it-all-down disruption? That’s reckless.
0
0
2